Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report

Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients. In patients who progress after chemotherapy, immune checkpoint inhibitor (ICI) monotherapy can prolong overall survival compared with patients receiving single-agent c...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yuling, An, Tongtong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493187/
https://www.ncbi.nlm.nih.gov/pubmed/34605304
http://dx.doi.org/10.1177/03000605211042988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493187/
https://www.ncbi.nlm.nih.gov/pubmed/34605304
http://dx.doi.org/10.1177/03000605211042988

Ejemplares similares